Progressive supranuclear palsy (PSP) is a rare movement disorder and often difficult to distinguish clinically from Parkinson's disease (PD) and multiple system atrophy (MSA) in early phases. In this study, we report reproducible disease-related topographies of brain network and regional glucose metabolism associated with PSP in clinically-confirmed independent cohorts of PSP, MSA, and PD patients and healthy controls in the USA and China. Using 18 F-FDG PET images from PSP and healthy subjects, we applied spatial covariance analysis with bootstrapping to identify a PSP-related pattern (PSPRP) and estimate its reliability, and evaluated the ability of network scores for differential diagnosis. We also detected regional metabolic differences using statistical parametric mapping analysis. We produced a highly reliable PSPRP characterized by relative metabolic decreases in the middle prefrontal cortex/cingulate, ventrolateral prefrontal cortex, striatum, thalamus and midbrain, covarying with relative metabolic increases in the hippocampus, insula and parieto-temporal regions.
| I N TR ODU C TI ON
Progressive supranuclear palsy (PSP) is one of the most common forms of atypical parkinsonism characterized by gait dysfunction, gaze palsy, cognitive impairment, early dysphagia and dysarthria. At early disease stages, PSP remains difficult to diagnose because of its substantial overlap of clinical symptoms with Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal degeneration and dementia with Lewy bodies. Despite progressive improvement in clinical diagnostic criteria for parkinsonian syndromes in the past few decades, it has been reported that approximately 20%-47% of patients with PSP are still misdiagnosed in life (Joutsa, Gardberg, Roytta, & Kaasinen, 2014; Respondek et al., 2013) . Given that disease prognoses and treatment options can differ considerably, a correct diagnosis of PSP from other types of parkinsonism is of great importance in clinical practice as well as in research trials of novel therapies.
Neuroimaging with positron emission tomography (PET) has been used extensively to provide increased accuracy of clinical diagnosis for PSP in vivo. So far, reduced striatal binding in dopaminergic imaging has demonstrated high sensitivity for detecting PSP and other forms of parkinsonism, but it has not been sufficiently accurate for discrimination among these diseases (Jin et al., 2013) . Although cholinergic deficiency in cortical and subcortical regions may be suggestive of PSP, this marker has shown neither sensitivity nor specificity, especially at early stages of the disease (Gilman et al., 2010; Hirano et al., 2010) . The application of functional imaging of neuropathology (i.e., tau fibrillar aggregates and b-amyloid deposition) is still in its infancy, thereby also being of limited value in early differential diagnosis of parkinsonism (Broski et al., 2014; Kepe et al., 2013) .
Brain metabolic activity measured with 18 F-fluorodeoxyglucose ( 18 F-FDG) PET has proven to be valuable for studying parkinsonian disorders (Eckert et al., 2005; Eckert et al., 2008; Niethammer & Eidelberg, 2012; Teune et al., 2010; Teune et al., 2013; Wu et al., 2013; Wu et al., 2014) . In the past decade, a variety of voxel-based techniques have been successfully applied to 18 F-FDG PET images to describe characteristic patterns of regional glucose metabolism in patients with PSP. To date, disease-specific metabolic markers associated with PSP have been reported in several independent patient cohorts to assist in early differential diagnosis on a single-case basis. This prospective application was facilitated qualitatively by visually inspecting the similarity of each 18 F-FDG PET image to PSP-related metabolic templates (Eckert et al., 2005; Teune et al., 2010) or quantitatively by assessing the activity of PSP-related metabolic networks (Eckert et al., 2008; Teune et al., 2013) .
These studies utilized two complementary (i.e., univariate or multivariate) analytical approaches but were limited by the lack of objective comparisons between the patterns across independent imaging centers.
Before the PSP-related metabolic marker can be used as a reference standard to help routine clinical diagnosis, it is necessary to assess its reproducibility on a whole-brain basis in a direct comparison of different patient cohorts using the same analytical techniques.
In this study, we used multivariate brain network analysis to identify, characterize and cross-validate PSP-related metabolic patterns (PSPRP) together and separately in an American cohort and a comparable Chinese cohort of both healthy control subjects and patients with parkinsonism.
We also evaluated similarities and differences in abnormal regional metabolism in these 18 F-FDG PET images using univariate brain mapping analysis. Moreover, we examined the reproducibility of PSP-specific metabolic characteristics and network biomarkers across study populations, PET instruments and analytical approaches.
| M A TER I A L A N D M ETH OD S

| Subjects
This study included two different cohorts of healthy subjects and parkinsonian patients. The first cohort were recruited from both American and Chinese populations resulting in a total of 100 participants: 20 normal controls along with 20 PSP, 20 MSA, and 40 PD patients. The
American cohort was comprised of 10 healthy subjects and 10 PSP, 10 MSA, and 20 PD patients recruited at North Shore University Hospital (NY, USA) and used originally for the identification and internal evaluation of disease-related metabolic patterns associated with parkinsonism (i.e., PSPRP, MSARP, and PDRP; Eckert et al., 2008; Ma, Tang, Spetsieris, Dhawan, & Eidelberg, 2007) . These patterns had played a critical role in the development and validation of novel classification algorithms for early differential diagnosis of parkinsonism in independent populations from different countries (Ko, Lee, & Eidelberg, 2017; Niethammer et al., 2014; Tang et al., 2010; Tripathi et al., 2016) . To match the sample size, the Chinese cohort consisted of the same numbers of healthy subjects and parkinsonian patients who were prospectively enrolled at Huashan Hospital (Shanghai, China) between January 2014 and September 2015. Demographic and clinical data for the healthy and patient groups are provided in Table 1 . In the combined cohort there was a trend effect of age among four subject groups (ANOVA: F Before taking part in this study, all patients were followed by two specialists of movement disorders at each institution for at least one year. The clinical diagnosis was further ascertained through postimaging follow-up by the clinicians who were blinded to the imaging results. All patients with PSP met the consensus diagnostic criteria for "probable" PSP (NINDS-SPSP; Litvan et al., 1996; Respondek et al., 2013) and showed vertical supranuclear palsy and prominent postural instability with tendency to fall in the first year of disease onset. All patients with MSA and PD satisfied the criteria of the Second Consensus Statement on the Diagnosis of MSA (Gilman et al., 2008) and the UK Brain Bank (Gibb & Lees, 1988) , respectively. These were clinicallyconfirmed patients at relatively advanced stages in order to identify and cross-validate disease-specific patterns.
However, most patients referred to scanning in clinical routine are more likely to be suspected of having parkinsonism at earlier stages. To more realistically assess differential diagnosis of parkinsonism, we
included a second independent Chinese cohort with a total of 68 participants: 20 normal controls and 14 PSP, 14 MSA and 20 PD patients (Table 2) . These patients were initially scanned with 18 F-FDG PET at the Chinese site as clinically uncertain cases, and then followed up for several years until a clinical diagnosis was made unequivocally by their neurologists. The subjects in this early patient cohort were at very early clinical stages (p < .05) compared to those in the combined American and Chinese cohort (Table 2) with less severe motor symptoms (PSP: p 5 .33; MSA or PD: p < .005) and shorter disease duration (p < .005). Normal control and PSP subjects were closed matched in age (p .25) but MSA and PD patients were younger (p < .001) compared to those in the combined cohort. No patients showed brain structural abnormalities (e.g., mass lesions and ischemia) on magnetic resonance imaging (MRI). All healthy controls participating in this study underwent a neurological examination by a senior movement disorders specialist to rule out history of neurologic or psychiatric disorders.
None of the patients and healthy volunteer subjects had any prior exposure to neuroleptic agents or drug use.
Ethical permission for the study procedures was obtained from the Institutional Review Boards at North Shore University Hospital and 
| 18 F-FDG PET imaging
All subjects were asked to fast for at least 6 hr but had free access to water prior to imaging. All patients underwent 18 F-FDG PET at least 12 hr after the cessation of oral antiparkinsonian medications. The
American subjects were scanned on a GE Advance Tomograph (General Electric, Milwaukee, WI) in three-dimensional (3D) mode (Ma et al., 2007) . Following a transmission scan, a PET scan was acquired over 35-45 min after an intravenous injection of 
| Network analysis
Brain network analysis and related computing procedures were performed using ScanVP software, Version 5. (Ma et al., 2007; Spetsieris & Eidelberg, 2011) . Briefly, the method executed PCA on covariance matrix of group-wise image data within a brain mask of gray matter for identifying a disease-related spatial covariance pattern with greater expression in patients than in control subjects. The pattern was defined by a linear combination of select principal components (PCs) whose expression could best discriminate the patients from the controls, as determined by the lowest Akaike Information Criterion (AIC) value in a logistical regression model. Subject scores of this pattern were computed prospectively in any other scans using a voxel-based topographic profile rating (TPR) algorithm. This entailed multiplying each individual image with that of the pattern (i.e., dot product between the two images) and summing the result over the brain mask. The resulting scores were then Z-transformed by using subject scores of the healthy controls involved in the pattern identification, that is, Z-score 5 (score -control mean)/control standard deviation.
| Pattern identification and disease discrimination
Specific metabolic pattern associated with PSP (PSPRP) were identified using 18 F-FDG PET data from the PSP and healthy subjects in the combined American and Chinese cohort. The reliability of this pattern was estimated at each voxel by means of an iterative bootstrapping scheme (Habeck et al., 2008; Peng et al., 2014) . This step produced a map of inverse coefficient of variation (ICV) to assess a brain-wide statistic.
Network scores of PSPRP were then computed for all scans in the combined cohort as well as in the early patient cohort and Z-scored using subject scores of the healthy controls in the identification cohort of PSPRP.
| Cross-validation of topographies and pattern expression between the USA and China
We next identified a separate PSPRP using were used to calculate the correlation between the two patterns. Subject scores of each pattern were calculated for the normal, PSP, MSA, and PD groups in each cohort and cross-validated by computing network scores of the PSPRP identified in the USA for the subjects in China or vice versa. Group discrimination was examined using the subject scores within each site and across the two sites. Moreover, the subject scores for the PSPRP identified in the USA were also correlated with those for the prospective validation of the PSPRP derived in China or vice versa.
| Analysis of regional metabolic activity
Differences in regional metabolism between patients and normal controls were analyzed using SPM5 as described previously 
| Statistical analysis
Differences in PSPRP scores between patients and normal controls
were assessed using two-sample t tests in the derivation cohort of each pattern. Changes in PSPRP score over multiple groups in one cohort or between the cohorts were evaluated using one-way analysis of variance (ANOVA) with differences between groups examined posthoc with Bonferroni tests. Discrimination power was determined by receiver operating characteristic (ROC) analysis. Relationships between PSPRP scores and clinical measures in patients or between two PSPRP scores in the same groups were determined by computing Pearson correlation coefficients. Group differences in regional metabolic values were assessed using two-sample t tests in a single cohort and one-way ANOVA across the two cohorts. All analyses used SPSS software (SPSS Inc., Chicago, IL) and were considered significant for p < .05. (Figure 1d ; Supporting Information Table S1 ).
Furthermore, PSPRP scores did not differ (p .17) between the two cohorts in the NL, PSP, and MSA subjects but were greater (p < .01) in the American patients with PD.
| Disease discrimination by pattern expression in early stage patients
There was also an effect of groups in PSPRP scores in Cohort 2 with parkinsonian patients at early stages (ANOVA: These scores were also greater in the PSP patients (p < .0001) than those in the MSA patients.
| Comparison of pattern expression
Subject scores of both PSPRPs for the four relevant groups are provided in Table 4 . ANOVA revealed an effect of group for the expres- More hyperactive regions that differ in abnormal metabolism between both cohorts were detected in anterior cingulate and superior temporal gyrus at a lower threshold (Supporting Information Table S3 ; p < .01).
| Group differences in relative regional metabolism in each cohort
For the American or Chinese cohort, compared to healthy subjects, PSP patients exhibited metabolic decreases or increases bilaterally in the same regions as revealed in the conjunction analysis described above (Supporting Information Tables S4 and S5 were also comparable by a cross validation with subject scores in prospective cohorts of PSP patients and healthy subjects. This was in accord with a previous study that reported reproducible network expression in multiple American patient groups scanned on the same PET camera (Eckert et al., 2008) . Secondly, we localized analogous differences in regional metabolic activity in the same groups of PSP patients and healthy subjects on a whole brain basis with SPM analysis.
We found that PSP patients from the two cohorts shared a large number of overlapping areas with abnormal metabolism in both cortical and subcortical regions. Post-hoc VOI analyses of relative metabolic values further confirmed the significant differences in these brain regions between the patient and control groups.
We need to emphasize that this work represented the first crossvalidation study to investigate reproducible metabolic abnormalities between truly independent cohorts of patients with PSP using two different analytical approaches. The spatial covariance analysis was aimed to derive a brain network with variance information in glucose metabolism in 18 F-FDG PET images from PSP patients and controls. By contrast, the SPM analysis was designed to capture regionally-specific differences in mean glucose metabolism between patients and controls.
They actually portrayed different but complementary measures of brain dysfunction. Therefore, the application of network and regional analyses used in this study is helpful in describing the pathophysiology of PSP at both the systems and local levels and may provide more valuable imaging biomarkers for the disease.
The current work demonstrated topographical similarities between the resulting patterns at the systems and local levels in both cohorts (together or individually), in agreement with previous reports in another independent cohort in the Netherlands (Teune et al., 2010; Teune et al., 2013) . Comparable distributions of abnormal regional metabolism between both cohorts in this study were responsible for the similarly elevated network scores of the two PSPRPs, given that subject score is a similarity measure between the topography of a covariance pattern and the metabolic distribution of a particular image. The high degree of comparability in the PSPRPs between the Chinese and American medical centers reported here is analogous to that for the Parkinson's disease-related patterns (i.e., PDRPs) from the same two centers (Wu et al., 2013) . Our work is part of an international collaborative effort to cross-validate the reproducibility of all PD-related network biomarkers.
Indeed, the expression of metabolic brain networks in multiple forms of parkinsonism has proven to be viable biomarkers for early differential diagnosis based on a series of rigorous multi-center validation studies performed prospectively in individual parkinsonian patients (Ko et al., 2017; Niethammer et al., 2014; Tang et al., 2010; Tripathi et al., 2016) .
Using both analytical approaches noted above, we observed metabolic decreases in the middle prefrontal/cingulate and ventrolateral prefrontal cortices, striatum, thalamus and midbrain in both cohorts of PSP patients. These findings were compatible with previous imaging studies that described reduced cerebral blood flow or metabolism in Furthermore, the loss of neurons in relevant regions verified by autopsy studies in PSP patients also provided support to our results (Pahapill & Lozano, 2000; Zweig et al., 1987) . The decreased metabolism in these cerebral regions is thought to be correlates of dysfunction in a supraspinal locomotor network (SLN). This network, including both indirect and direct pathways, is considered to be responsible for gait control in human beings (Bohnen & Jahn, 2013; Zwergal et al., 2013) .
Indeed, the indirect pathway of SLN runs from the frontal cortex via the basal ganglia to the brainstem locomotor centers, allowing for the modulation of gait pattern in response to external demands. By contrast, the direct pathway of SLN goes from the motor cortex to the spinal cord, bypassing the brainstem centers and playing a more important role during undisturbed locomotion. The normal function of the indirect pathway in SLN is largely disturbed in PSP by decreased regional metabolism. Although the direct pathway subsequently overprojects as an early compensatory mechanism, it cannot adequately adapt to environmental demands, causing gait impairment (e.g., akinesia and freezing of gait) in the PSP patients. This assumption is further supported by increased metabolic activity in the cortices surrounding paracentral lobule (including mainly primary motor cortex and supplementary motor area) as observed in the present study, likely reflecting compensation for the direct pathway in SLN.
All PSP patients in this study exhibited upward or downward vertical gaze palsy, a feature with high specificity for differentiating PSP from other parkinsonian syndromes, as was also evident in the discrimination outcome by PSPRP network activity. In accordance with this clinical symptom and network association, we observed a decrease in metabolism in the medial frontal cortex, the area responsible for the control of eye movements in healthy volunteers (Hanakawa, Dimyan, & Hallett, 2008; Paus, Petrides, Evans, & Meyer, 1993) . This is compatible with prior imaging studies reporting significant correlation of vertical gaze palsy with decreased metabolism in the same area (Amtage et al., 2014) . Given that the frontal cortex is involved with normal function of executive tasks, the early onset of cognitive impairment in PSP may also be related to hypometabolism in this region (Kim, Lee, & Lee, 2014; Lee, Williams, & Anderson, 2016) . Pseudobulbar palsy such as dysphagia and dysarthria is another supportive criterion for clinical diagnosis of PSP.
This condition is usually caused by damage to the neurons of the brainstem, specifically to the corticobulbar tract. In this vein, we may attribute the decreased metabolism of midbrain observed in this study as an indication of pseudobulbar palsy in PSP. Nevertheless, more studies are needed to provide clearer evidence on this correlation.
This study also revealed increased metabolism in the territories of hippocampus or parahippocampus and temporal cortex in both cohorts of patients with PSP. While abnormal metabolism in hippocampus/parahippocampus was reported in PSP patients (Teune et al., 2010) , altered structures in these regions were also noted previously in several anatomical MRI studies (Agosta et al., 2010; Messina et al., 2011; Padovani et al., 2006; Saini et al., 2013) . The reasons for such abnormalities still remain unclear, but in all likelihood result from activations by specific circuits in the basal ganglia (Albin, Young, & Penney, 1989) and may be related with early cognitive impairment in PSP patients.
Hypermetabolism in temporal lobe has also been described in prior functional imaging studies (Teune et al., 2010) , and it is plausible that Subject scores and regional metabolic values are presented as mean 6 SD. PSPRP activity values marked bold indicated subject scores in the original derivation cohort with the other values computed prospectively in the validation cohort. The regional metabolic values were computed post-hoc following the SPM analysis as shown in Figure 6b -g and Figure 7b . F values came from analysis of variance for each measure across the four independent subject groups. a The peak coordinates in the Montreal Neurological Institute (MNI) standard space.
SPM 5 statistical parametric mapping; SSM/PCA 5 scaled subprofile modeling based on principal component analysis.
increased metabolism in this region may reflect elevated sensory control in patients with PSP. We also replicated the previous finding of increased regional metabolism in the insula, middle occipital gyrus and cerebellum (Teune et al., 2010 ). While there is a possible link between cerebellar abnormality and impaired balance capacity in PSP patients, metabolic changes in insula and occipital gyrus may be explained by deficient hand-eye motor movement and mild cognitive dysfunction in patients (Anderson et al., 1994) . 
| 2853
The imaging results reported in this study are generally compatible with demographic and clinical features of subject groups that are closely matched between the American and Chinese cohorts ( Table 1 ).
The distribution of these features among different groups is highly representative of sample populations encountered in clinical practice, particularly in the combined cohort. Hence, we used the combined (Tables 1 and 2) , PSPRP scores did not show any differences or correlations with respect to these variables suggesting that age/gender do not play a big role in PSP-related network analysis and have no effect on performance in differential diagnosis.
The patients recruited for the primary analyses in this study were all clinically-confirmed with at least one-year follow-up at the time of To this end we found that PSPRP activity can still discriminate PSP from other groups in the second cohort of patients with early, clinically unclassifiable parkinsonism (Figure 2) . PSPRP scores were lower in each of these patient groups than those in the combined American and Chinese cohort (see Supporting Information Figure S4 ). It is expected that diagnostic performance of quantitative metabolic network activity reported in the current study can be further improved in realistic clinical practice with the use of the novel classification algorithm including metabolic brain networks in other forms of parkinsonism (Tang et al., 2010; Tripathi et al., 2016) .
Over the last few decades, high resolution MRI scanners combined with advanced quantitative techniques have contributed significantly to measurements of structural and functional changes for the discrimination of PSP from other forms of parkinsonism Whitwell et al., 2017) . Currently, magnetic resonance parkinsonism index (MRPI) appears to be one of the most mature MRI biomarkers for assessing subcortical atrophy of PSP, which was defined by multiplying the area ratio of pons to midbrain by the width ratio of middle to superior cerebellar peduncles. It has been recently reported that MRPI could yield very high sensitivity of 100% and specificity of 99.2%-100% for PSP (Nigro et al., 2017) and was also able to predict development of the disease (Whitwell et al., 2017) . In response to the great progress in MRI we have initiated a research project to develop and cross-validate PET-and MRI-based brain network biomarkers in parkinsonism using modern multimodality neuroimaging techniques. By computing PSPRP activity in a large cohort with both Despite the high degrees of similarity across the two cohorts there remain some inherent discrepancies as a result of inevitable differences in subject characteristics, scanner designs and imaging protocols. We further note that the Chinese PSP patients had more severe symptoms and longer duration than their American counterparts though not significantly different. Albeit not prominent, some differences in PSPrelated metabolic characteristics across the patient populations and scanners were reported in this study regardless which analytic approach was used. Indeed, network activity of PSPRP in China was greater but more variable in the Chinese patients than in the American patients, and had lower degrees of correlations per subject group than PSPRP in the USA. Furthermore, metabolic increases were observed in the cerebellum mainly in the Chinese patients with PSP but in the occipital regions predominately in the American patients. We also found that cuneus metabolism in PSP patients was decreased in the Chinese cohort but elevated in the American cohort. The noisier and variable data in the Chinese cohort may be attributed to the PET/CT scanner known to have higher variability than the dedicated PET camera, owe to the use of different attenuation correction methods (CT vs. PET transmission scanning) and reconstruction algorithms (iterative vs. analytical) in the creation of PET emission images. Nonetheless, as these disease-related metabolic characteristics are highly reproducible in major cerebral regions of PSP patients on a whole brain basis and PSPRP activity can accurately differentiate PSP from other forms of parkinsonism, it strongly suggested that such a pattern is well-qualified to offer a specific and reliable imaging marker for clinical diagnosis of PSP.
Several limitations should be noted in this study: (1) in the absence of neuropathological confirmation of PSP in our patient cohorts we relied on the clinical diagnostic accuracy of movement disorders experts at each site. This was a valuable strategy reflecting how PSP is diagnosed in the real-world; (2) the sample sizes of PSP patients and healthy controls were relatively small at both sites so as to conform to the PSPrelated metabolic pattern already established in the USA. These limited samples might be justifiable given the more severe metabolic abnormalities inherent in this rapidly degenerative disease. This issue was mostly mitigated by combining all PET images from the two sites in a series of primary analysis reported in this article. The fact that analogous metabolic patterns were identified across two independent cohorts suggest that the clinical diagnosis were accurate and the sample sizes were adequate in this study; (3) the relationship of brain glucose metabolism to clinical measures of disease severity and cognitive dysfunction has not been fully demonstrated due to the limited samples, and despite the observed correlation of network activity with PSP duration; (4) the present study did not exclusively classify patients with subtypes of PSP. Our PSP patients had predominately Richardson's syndrome based on primary clinical features present at follow-up. It will be still necessary to replicate the results reported here in different PSP variants and to identify corresponding clinical correlates with larger sample sizes. 
